Net Loss of Oxygenta Pharmaceutical reported to Rs 4.93 crore in the quarter ended September 2025 as against net loss of Rs 2.85 crore during the previous quarter ended September 2024. Sales rose 2.07% to Rs 14.30 crore in the quarter ended September 2025 as against Rs 14.01 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales14.3014.01 2 OPM %-31.96-15.49 - PBDT-5.58-2.11 -164 PBT-6.44-2.77 -132 NP-4.93-2.85 -73 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live News

Oxygenta Pharmaceutical announced that the 32th Annual General Meeting(AGM) of the company will be held on 19 September 2025.Powered by Capital Market - Live News

Net Loss of Oxygenta Pharmaceutical reported to Rs 6.11 crore in the quarter ended June 2025 as against net loss of Rs 1.36 crore during the previous quarter ended June 2024. Sales rose 19.89% to Rs 15.13 crore in the quarter ended June 2025 as against Rs 12.62 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales15.1312.62 20 OPM %-45.14-14.03 - PBDT-7.29-2.16 -238 PBT-8.14-2.81 -190 NP-6.11-1.36 -349 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live News